On the second night of the largest annual European cancer conference, some 100 Merck scientists packed into Champeaux, a classic French restaurant, to break bread and share clinical wisdom. It was ...
In 2022, Merck’s KEYTRUDA and GARDASIL worldwide sales increased by 27% YoY. The immunotherapy and HPV vaccines markets are expected to grow in the following years. The company’s cash and capital ...
11d
Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook
Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback